Black Diamond Therapeutics (BDTX) Competitors $2.06 -0.11 (-4.84%) As of 12:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BDTX vs. ERAS, KMDA, VERV, TECX, ORIC, RAPP, RVNC, ORGO, TKNO, and MBXShould you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Erasca (ERAS), Kamada (KMDA), Verve Therapeutics (VERV), Tectonic Therapeutic (TECX), ORIC Pharmaceuticals (ORIC), Rapport Therapeutics (RAPP), Revance Therapeutics (RVNC), Organogenesis (ORGO), Alpha Teknova (TKNO), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry. Black Diamond Therapeutics vs. Erasca Kamada Verve Therapeutics Tectonic Therapeutic ORIC Pharmaceuticals Rapport Therapeutics Revance Therapeutics Organogenesis Alpha Teknova MBX Biosciences Erasca (NASDAQ:ERAS) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, community ranking and media sentiment. Which has preferable valuation & earnings, ERAS or BDTX? Black Diamond Therapeutics has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$125.04M-$0.62-2.06Black Diamond Therapeutics$70M1.76-$82.44M$0.0636.17 Do institutionals and insiders hold more shares of ERAS or BDTX? 67.8% of Erasca shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 14.4% of Erasca shares are owned by company insiders. Comparatively, 8.9% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate ERAS or BDTX? Erasca currently has a consensus target price of $4.57, indicating a potential upside of 257.14%. Black Diamond Therapeutics has a consensus target price of $14.60, indicating a potential upside of 572.81%. Given Black Diamond Therapeutics' higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ERAS or BDTX more profitable? Erasca's return on equity of -42.26% beat Black Diamond Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -42.26% -34.97% Black Diamond Therapeutics N/A -68.08%-49.65% Does the media favor ERAS or BDTX? In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Erasca. MarketBeat recorded 9 mentions for Black Diamond Therapeutics and 8 mentions for Erasca. Black Diamond Therapeutics' average media sentiment score of 1.33 beat Erasca's score of 0.98 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Diamond Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer ERAS or BDTX? Black Diamond Therapeutics received 25 more outperform votes than Erasca when rated by MarketBeat users. However, 73.17% of users gave Erasca an outperform vote while only 71.43% of users gave Black Diamond Therapeutics an outperform vote. CompanyUnderperformOutperformErascaOutperform Votes3073.17% Underperform Votes1126.83% Black Diamond TherapeuticsOutperform Votes5571.43% Underperform Votes2228.57% Which has more risk & volatility, ERAS or BDTX? Erasca has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.63, meaning that its stock price is 163% more volatile than the S&P 500. SummaryBlack Diamond Therapeutics beats Erasca on 9 of the 15 factors compared between the two stocks. Get Black Diamond Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDTX vs. The Competition Export to ExcelMetricBlack Diamond TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$123.39M$2.97B$5.42B$8.48BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-1.6331.5826.8020.05Price / Sales1.76414.63393.93116.47Price / CashN/A168.6838.2534.62Price / Book0.963.376.864.61Net Income-$82.44M-$72.17M$3.22B$248.19M7 Day Performance14.81%18.10%6.81%2.97%1 Month Performance45.64%20.85%13.72%16.58%1 Year Performance-56.34%-24.45%18.24%8.16% Black Diamond Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDTXBlack Diamond Therapeutics3.3631 of 5 stars$2.07-4.8%$14.60+607.0%-55.7%$117.42M$70M-1.5590News CoveragePositive NewsERASErasca3.6538 of 5 stars$1.39flat$4.83+247.7%-42.9%$393.77MN/A-1.67120KMDAKamada3.9871 of 5 stars$6.82-0.9%$14.67+115.1%+26.8%$392.01M$160.95M24.36360Earnings ReportAnalyst RevisionVERVVerve Therapeutics3.5594 of 5 stars$4.35+2.8%$25.75+492.0%-22.5%$387.77M$32.33M-1.77110Trending NewsEarnings ReportAnalyst RevisionGap DownTECXTectonic Therapeutic3.6625 of 5 stars$20.71+4.8%$72.40+249.6%N/A$386.68MN/A-3.52120Positive NewsGap UpORICORIC Pharmaceuticals4.4986 of 5 stars$5.41+6.5%$19.17+254.3%-37.6%$384.59MN/A-2.9780Positive NewsRAPPRapport Therapeutics1.8071 of 5 stars$10.47+2.1%$32.67+212.0%N/A$382.13MN/A-3.03N/APositive NewsRVNCRevance Therapeutics1.9451 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Analyst ForecastORGOOrganogenesis4.0735 of 5 stars$2.98-2.6%$5.50+84.6%+17.7%$378.03M$482.04M-49.67950News CoverageGap UpTKNOAlpha Teknova1.7799 of 5 stars$7.06+1.4%$8.50+20.4%+275.4%$377.29M$37.75M-9.54240Gap UpMBXMBX Biosciences2.9921 of 5 stars$11.14+0.3%$37.50+236.6%N/A$372.34MN/A0.0036News CoveragePositive News Related Companies and Tools Related Companies ERAS Competitors KMDA Competitors VERV Competitors TECX Competitors ORIC Competitors RAPP Competitors RVNC Competitors ORGO Competitors TKNO Competitors MBX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BDTX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BDTX Stock Free BDTX Stock Alerts